Teleflex Declares Quarterly Dividend
Teleflex Incorporated (NYSE: TFX), based in Wayne, Pennsylvania, has proudly announced a quarterly cash dividend of $0.34 per share of its common stock. This declaration is a testament to the company's ongoing commitment to providing value to its shareholders. The dividend will be payable on March 17 to those shareholders who are on record as of March 7. Such initiatives reflect Teleflex's strong financial performance and its dedication to returning capital to its investors.
Commitment to Shareholders
At Teleflex, we understand that dividends are an important part of the total return for many investors. By declaring this dividend, we are continuing our tradition of rewarding our shareholders and demonstrating confidence in our business strategy and operational performance. Teleflex continues to explore avenues for sustainable growth and profitability, ensuring we not only achieve but exceed our shareholders' expectations.
A Leader in Medical Technology
Teleflex is more than just a company that pays dividends; it is a leading global provider of medical technologies dedicated to enhancing the health and quality of people’s lives. With a clear vision to become the most trusted healthcare partner, Teleflex offers a robust portfolio of solutions across various medical therapy areas such as anesthesia, emergency medicine, interventional cardiology and radiology, as well as surgical, vascular access, and urology.
Diverse Portfolio of Trusted Brands
Among the well-known brands under the Teleflex umbrella are Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™, and Weck™. These brands are united by a common purpose: to develop innovative solutions for healthcare providers and patients alike. This diverse portfolio underscores Teleflex's commitment to advancing healthcare while addressing some of the critical challenges in the medical field.
Investing in the Future
As Teleflex continues its journey, the focus remains sharply on empowering the future of healthcare. The company is committed to investing in research and development to foster purpose-driven innovation that can lead to groundbreaking advancements in medical technology. Our goal is not only to enhance our product offerings but also to ensure that healthcare systems worldwide can leverage our solutions effectively.
Continuous Improvement and Innovation
Each product developed by Teleflex is the result of extensive research and collaboration with healthcare professionals. This approach ensures that every solution is carefully engineered to meet the growing and evolving needs of patients and providers. The team's commitment to quality and safety is evident in every stage of product development, reinforcing Teleflex's reputation in the industry.
Contact Information
For any inquiries or further details, please reach out to the Teleflex Investor Relations team:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
Email: investor.relations@teleflex.com
Phone: 610-948-2836
Frequently Asked Questions
What is the amount of the declared dividend by Teleflex?
The declared dividend by Teleflex is $0.34 per share of common stock.
When will the dividend be paid?
The dividend is scheduled to be paid on March 17 to shareholders on record as of March 7.
What are some of the key brands owned by Teleflex?
Teleflex owns several trusted brands including Arrow™, LMA™, and QuikClot™.
How does Teleflex support healthcare innovation?
Teleflex invests in research and development to create innovative medical technologies that improve patient care.
Whom can I contact for investor relations at Teleflex?
You can contact Lawrence Keusch, Vice President of Investor Relations, at investor.relations@teleflex.com or call 610-948-2836.
